As 2026 begins, the American Society of Clinical Oncology is reporting a record shift toward blood-based genomic profiling as the primary diagnostic gateway for respiratory malignancies. Recent federal policy updates have standardized the use of high-sensitivity detection kits for high-risk populations, moving away from traditional tissue-heavy procedures. This transition is being driven by the...
Tiếng Việt 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)